Arama Sonuçları - Meghna Jani
- Gösterilen 1 - 15 sonuçlar arası kayıtlar. 15
-
1
Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far Yazar: Meghna Jani, William G Dixon, Hector Chinoy
Baskı/Yayın Bilgisi 2017Revisão -
2
Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? Yazar: Meghna Jani, Anne Barton, Kimme L Hyrich
Baskı/Yayın Bilgisi 2019Revisão -
3
The Genetics of Psoriasis and Psoriatic Arthritis Yazar: Darren D. O’Rielly, Meghna Jani, Proton Rahman, James T. Elder
Baskı/Yayın Bilgisi 2019Artigo -
4
Glucocorticoid use is associated with an increased risk of hypertension Yazar: Ruth Costello, Belay Birlie Yimer, P Roads, Meghna Jani, William G Dixon
Baskı/Yayın Bilgisi 2020Artigo -
5
-
6
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases Yazar: Meghna Jani, Anne Barton, Richard B. Warren, C.E.M. Griffiths, Hector Chinoy
Baskı/Yayın Bilgisi 2013Revisão -
7
-
8
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine Yazar: Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad, Silje Watterdal Syversen
Baskı/Yayın Bilgisi 2022Revisão -
9
Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in Northwest England Yazar: Belay Birlie Yimer, Mehreen Soomro, John McBeth, Carlos Raul Ramirez Medina, Mark Lunt, William G Dixon, Meghna Jani
Baskı/Yayın Bilgisi 2025Artigo -
10
High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS... Yazar: Meghna Jani, John D. Isaacs, Ann W. Morgan, Anthony G. Wilson, Darren Plant, Kimme L Hyrich, Hector Chinoy, Anne Barton
Baskı/Yayın Bilgisi 2016Artigo -
11
Deficient transcription of XIST from tiny ring X chromosomes in females with severe phenotypes. Yazar: Barbara R. Migeon, Shengyuan Luo, Beth A. Stasiowski, Meghna Jani, Joyce Axelman, Daniel L. Van Dyke, Lester Weiss, P. A. Jacobs, Teresa L. Yang‐Feng, John E. Wiley
Baskı/Yayın Bilgisi 1993Artigo -
12
Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis Yazar: Meghna Jani, Hector Chinoy, Richard B. Warren, C.E.M. Griffiths, Darren Plant, Bo Fu, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, Kimme L Hyrich, Anne Barton
Baskı/Yayın Bilgisi 2015Artigo -
13
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases Yazar: Annette de Thurah, Philipp Bösch, Andréa Marques, Yvette Meißner, Chetan Mukhtyar, Johannes Knitza, Aurélie Najm, Nina Østerås, Tim Pelle, Line Raunsbæk Knudsen, Hana Šmucrová, Françis Berenbaum, Meghna Jani, Rinie Geenen, Martin Krusche, Polina Pchelnikova, Savia de Souza, Sara Badreh, Dieter Wiek, Silvia Piantoni, James M. Gwinnutt, Christina Duftner, Helena Canhão, Luca Quartuccio, Nikolay Stoilov, Yeliz Prior, J. W. J. Bijlsma, Alen Zabotti, Tanja Stamm, Christian Dejaco
Baskı/Yayın Bilgisi 2022Revisão -
14
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases Yazar: C. Krieckaert, Astrid van Tubergen, Johanna Elin Gehin, Borja Hernández‐Breijo, Guillaume Le Mélédo, Alejandro Balsa, Peter Böhm, Saša Čučnik, Ori Elkayam, Guro Løvik Goll, Femke Hooijberg, Meghna Jani, Patrick Kiely, Neil E. McCarthy, Denis Mulleman, Victoria Navarro‐Compán, Katherine Payne, Martin E Perry, Chamaida Plasencia‐Rodríguez, Simon Stones, Silje Watterdal Syversen, Annick de Vries, Katherine M Ward, Gertjan Wolbink, John D. Isaacs
Baskı/Yayın Bilgisi 2022Revisão -
15
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Yazar: Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, J. Nam, Sofía Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Christopher D. Buckley, Frank Buttgereit, Vivian P. Bykerk, Myrna Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan J. Gómez‐Reino, Laure Gossec, J.-E. Gottenberg, Johanna M W Hazes, T. Huizinga, Meghna Jani, Д. Е. Каратеев, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain B. McInnes, Eduardo Mysler, Peter Nash, Karel Pavelká, Gyula Poór, Christophe Richez, Piet L. C. M. van Riel, Andrea Rubbert‐Roth, Kenneth G. Saag, José António Pereira da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Baskı/Yayın Bilgisi 2017Revisão
Arama Araçları:
İlgili Konular
Medicine
Internal medicine
Pharmacology
Drug
Adalimumab
Immunology
Intensive care medicine
Rheumatoid arthritis
Biology
Disease
Adverse effect
Antibody
Clinical trial
Cohort
Cohort study
Etanercept
Genetics
Immunogenicity
Infliximab
Retrospective cohort study
Rheumatism
Cancer
Cancer pain
Certolizumab pegol
Computer science
Environmental health
Gastroenterology
Gene
Pharmacovigilance
Physical therapy